HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
meproscillarin
semi-synthetic derivative of proscillaridin of Scilla (Liliaceae); structure in Negwer, 5th ed, #6625; RN given refers to (3beta)-isomer
Also Known As:
methylproscillaridin; proscillaridin 4'-methyl ether
Networked:
10
relevant articles (
0
outcomes,
0
trials/studies)
Bio-Agent Context: Research Results
Polycyclic Compounds: 6
Fused-Ring Compounds
Steroids: 70059
Cardanolides
Cardiac Glycosides: 1002
Bufanolides: 91
Proscillaridin: 56
meproscillarin: 10
Carbohydrates: 22023
Glycosides: 2119
Cardiac Glycosides: 1002
Proscillaridin: 56
meproscillarin: 10
Related Diseases
1.
Renal Insufficiency (Renal Failure)
11/23/1979 - "
It was to be investigated whether a good cardiac effectiveness can be demonstrated during oral long-term application of meproscillarin to patients with renal failure.
"
11/23/1979 - "
29 patients with renal failure of varying degree and concomitant heart failure were daily given an oral dose of 0.75 mg of meproscillarin over 14 days.
"
11/23/1979 - "
[Meproscillarin in patients with renal failure and concomitant heart failure (author's transl)].
"
01/01/1978 - "
A group of 9 patients with renal insufficiency of varying extent associated with heart failure received 0.75 mg of meproscillarin per day over a period of 14 days.
"
01/01/1978 - "
With a rate of inactivation of about 40% and a bioavailability of about 70% corresponding approximately to that of digoxin 14-hydroxy-3beta-[(4-O-methyl-alpha-L-rhamnopyranosyl)oxy]-14beta-bufa-4,20,22-trienolide (meproscillarin, Clift) is--according to our results--a new therapeutic possibility for cardiac decompensated patients, especially in the presence of renal failure.
"
2.
Heart Failure
11/23/1979 - "
29 patients with renal failure of varying degree and concomitant heart failure were daily given an oral dose of 0.75 mg of meproscillarin over 14 days.
"
11/23/1979 - "
[Meproscillarin in patients with renal failure and concomitant heart failure (author's transl)].
"
01/01/1978 - "
A group of 9 patients with renal insufficiency of varying extent associated with heart failure received 0.75 mg of meproscillarin per day over a period of 14 days.
"
01/01/1978 - "
In 10 patients with arterial hypertension and left heart failure the hemodynamic effect of 14-hydroxy-3-beta-[4-O-methyl-alpha-L-rhamnopyranosyl)oxy]-14beta-bufa-4,20,22-trienolide (Ky 18, meproscillarin, Clift) was compared with placebo in a double-blind study.
"
11/23/1979 - "
As the pharmacokinetics of the glycoside is practically not influenced by the renal function, meproscillarin represents an alternative in the treatment of patients with heart failure and impaired renal function.
"
3.
Biliary Fistula
01/01/1978 - "
The investigations on the metabolism of 14-Hydroxy-3beta-[(4-O-methyl-alpha-L-rhamnopyranosyl)oxy]-14beta-bufa-4,20,22-trienolide (meproscillarin, Clift) were performed in 5 healthy test persons as well as in 4 patients with biliary fistula, applying a single oral dose of 0.5 mg of 3H-meproscillarin.
"
12/19/1975 - "
Excretion of methylproscillaridin in patients with a biliary fistula.
"
4.
Liver Cirrhosis (Hepatic Cirrhosis)
01/01/1983 - "
With this limitation Meproscillarin can be used therapeutically in patients with liver cirrhosis, because a toxic accumulation is not to be expected.
"
01/01/1983 - "
Compared with the control group no difference was detected in the elimination rate of Meproscillarin in patients with liver cirrhosis, which means a complex disturbed liver function.
"
01/01/1983 - "
During a one week period patients with liver cirrhosis and a control group were treated with a repeated dosage of the new heart glcoside Meproscillarin.
"
01/01/1983 - "
Nevertheless the greater variance of the Meproscillarin plasma levels in the patients with liver cirrhosis in comparison with the controls means a diminished predictability of the therapeutic success in the cirrhosis group.
"
01/01/1983 - "
[Plasma concentration and elimination behavior of the cardiac glycoside meproscillarin in patients with liver cirrhosis].
"
5.
Hypertension (High Blood Pressure)
01/01/1978 - "
In 10 patients with arterial hypertension and left heart failure the hemodynamic effect of 14-hydroxy-3-beta-[4-O-methyl-alpha-L-rhamnopyranosyl)oxy]-14beta-bufa-4,20,22-trienolide (Ky 18, meproscillarin, Clift) was compared with placebo in a double-blind study.
"
Related Drugs and Biologics
1.
Glycosides
2.
Digoxin (Digitek)
3.
Cardiac Glycosides